Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the safety and efficacy of CB-03-01 solution in men with androgenetic alopecia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Androgenetic Alopecia

Drugs mentioned

• CB-03-01

Snippet

Sponsor: Intrepid Therapeutics, Inc. | Conditions: Androgenetic Alopecia | Phase 2 | Status: COMPLETED